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1. Introduction 
Diagnostic accuracy in regard to biliary and pancreatic diseases has improved markedly 
since the introduction of computed tomography (CT) and magnetic resonance 
cholangiopancreatography (MRCP)(1,2), but detection of small bile duct cancers and small 
pancreatic cancers is difficult even by those modalities. Endoscopic retrograde 
cholangiopancreatography (ERCP) remains the most accurate and reliable procedure for 
cytodiagnosis and precise staging of biliary and pancreatic neoplasms, and it is 
indispensable to the endoscopic treatment of biliary and pancreatic diseases. 
Pancreatitis remains the most common complication of ERCP and results in substantial 
morbidity and, occasionally, in death (3-5). The mechanisms responsible for the 
development of post-ERCP pancreatitis are not fully understood, but they are thought to be 
multifactorial. A number of specific risk factors have been proposed as predictors of post-
ERCP pancreatitis (6-15), and they include patient-, endoscopist-, and procedure-related 
factors. We therefore think that clear identification of risk factors is facilitated by analyzing 
the data for diagnostic ERCP and therapeutic ERCP separately. 
Early identification of patients who are likely to develop post-procedure pancreatitis is 
highly desirable in terms of planning long-term follow-up in the hospital and an early 
therapeutic approach. Hyperamylasemia is common after ERCP, and amylase values have 
been found to peak between 90 min and 4 h post-ERCP (16,17). Testoni et al. (18) concluded 
that the serum amylase level measured 4 h after endoscopic sphincterotomy was the most 
reliable predictor of post-ERCP pancreatitis, and Thomas et al.(19) showed that the 4-h post-
procedure amylase level is clinically significant as a predictor of post-ERCP pancreatitis. We 
therefore hypothesized that the 4-h amylase level is the most accurate amylase value for 
predicting subsequent pancreatitis. 
Several studies (20-24) have demonstrated that the serum lipase level is more sensitive 
indicator than the serum amylase level for diagnosing other forms of acute pancreatitis, but 
only a few studies (25-27) have compared measurements of various pancreatic enzymes as a 
means of predicting post-ERCP pancreatitis. Moreover, it is still unclear whether there are 
differences in the diagnostic accuracy of pancreatic enzyme levels for predicting post-ERCP 
pancreatitis according to the procedures, in other words, whether the ERCP is diagnostic or 
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therapeutic. In the present study we evaluated the 4-h post-ERCP serum amylase level and 
serum lipase level as predictors of pancreatitis, with special focus on comparison of the two 
as a means of predicting post-ERCP pancreatitis, in a retrospective single-center design in 
Japan. 
2. Patients and methods 
We conducted a retrospective study in a single center by reviewing the 1631 consecutive 
cases in which ERCP was performed between January 1999 and December 2004 and 
(male:female ratio= 974:657 (1.48/1) ; age range 8-97 years old, median 67 years old). 
Diagnostic ERCP had been performed in 910 cases (male:female ratio=518:392 (1.32/1); age 
range 8-90 years old, median 63 years old), and therapeutic ERCP in 721 cases (male: female 
ratio=456:265 (160/1); age range 19-97 years old, median 67 years old). All patients were 
enrolled in this study, and there were no exclusion criteria. Diagnostic ERCP included 
brushing cytology (biliary tract, pancreatic duct) and intraductal ultrasonography (IDUS). 
Therapeutic ERCP included endoscopic papillary balloon dilatation (EPBD), endoscopic 
sphicterotomy (EST), stone removal, and bile duct drainage. 
All ERCP patients were intravenously infused over 4 hours with one of the following 
protease inhibitor solutions beginning 30 minutes before the ERCP examination: Gabexate 
mesilate 200 mg in 0.9% saline, 500 ml, Nafamostat mesilate 20 mg in 0.9 % saline, 500 ml; or 
Ulinastatin 50,000 U in 0.9 % saline, 500 ml. The choice of inhibitor was at the discretion of 
the chief physician responsible for the patient’s care. 
All patients remained in the hospital for at least 24 hours after the procedure to monitor 
them for clinical manifestations of pancreatitis. Serum amylase and lipase levels were 
measured before and 4 and 16-18 hours (the next morning) after ERCP. We evaluated 23 
variables, including patient-related factors, an endoscopist-related factor, and procedure-
related factors that could be analyzed in detail based on information in the patients’ charts. 
We also evaluated and compared the 4-h post-ERCP serum amylase level and serum lipase 
level as predictors of pancreatitis based on receiver-operator characteristic (ROC) curves. To 
compare the ROC curves, we analyzed only the data from cases in which both amylase and 
lipase could be measured, in other words, we made a matched pair comparison. We 
analyzed the data of a total of 1267 patients, consisting of 65 pancreatitis patients and 1202 
non-pancreatitis patients. A total of 688 patients, consisting of 39 pancreatitis patients and 
649 non-pancreatitis patients had undergone diagnostic ERCP, and a total of 579 patients, 
consisting of 26 pancreatitis patients and 553 non-pancreatitis patients, had gone therapeutic 
ERCP.  
Data related to the procedures were gathered in a prospective manner, but the global 
analysis was performed in a retrospective manner. 
2.1 Endoscopists 
The 1631 ERCP procedures were performed by 11 different endoscopists (median: 57 
procedures per endoscopist, range: 8-423). Four of the endoscopists performed about 84% of 
the procedures, and each of the 4 had performed more than 200 ERCPs before the study. The 
other 7 endoscopists had performed fewer than 200 ERCPs each before the study. 
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2.2 Definition 
High levels of emzymes was defined as an amylase level (normal range: 40-125 IU/l) and 
/or lipase level (normal range 13-49 IU/l) above the upper limit of the normal range. The 
criteria for the diagnosis of post-ERCP pancreatitis were: (1) abdominal pain that persisted 
for at least 24 hours; (2) a serum amylase level and/or lipase level measured 16-18 hours 
after the procedure (next morning) that was more than three times the upper limit of the 
normal range; (3) pancreatic swelling with or without fluid collection on an abdominal US 
and/or CT examination the next morning. Fulfillment of criterion 1 plus criterion 2 and/or 3 
was required to make the diagnosis. Pancreatitis was graded as follows according to the 
scoring system proposed by the Ministry of Health, Labour and Welfare of Japan (JPN 
score) (28,29): mild (0 points); moderate (1 point); severe (2 points or more). 
The injection pressure of contrast medium into the pancreatic duct was scored as follows 
based on the degree of pancreatic duct visualization, according to a modification of the 
criteria proposed by Tsujino et al. (30): 0, no pancreatic duct visualization; 1, visualization of 
the main pancreatic duct alone; 2, 1 and visualization of primary branches; 3, 2 and 
visualization of secondary branches; and 4, 3 and/or visualization of acini (acinarization). 
2.3 Statistical analysis 
In the first step, a univariate analysis was performed by the chi-square method for each of 
the potential risk factors. In the second step, factors with a p value <0.2 according to the chi-
square analysis were included in a multivariate (logistic regression) analysis performed 
using Statview 5.0 software. A p value <0.05 was considered statistically significant. The 
odds ratios are reported with their 95% confidence limits. 
ROC curve analyses for the serum amylase and lipase values were performed using 
Medcalc software. We assessed whether the difference in area under two ROC curves was 
significant based on the methods proposed by Hanley JA et al (31). In short, the difference in 
area under two ROC curves derived from the same set of patients is calculated as a critical 
ratio z by using the formula: 
z= (A1-A2)/√(SE12+SE22-2rSE1SE2),  
where A1 is the observed area and SE1 is estimated error of the ROC area associated with 
modality 1, A2 and SE2 are the corresponding values for modality 2, and r is a constant 
calculated from (A1+A2)/2 and (rn+ra)/2, where rn is the coefficient for the correlation 
between modality 1 and modality 2 in the control group (non-pancreatitis group in this 
study), and ra is the coefficient for the correlation between modality 1 and modality 2 in the 
diseased group (pancreatitis group in this study). This quantity z is then referred to tables of 
the normal distribution and values of z above a certain cutoff are taken as evidence of a 
difference between the ‘true’ ROC areas. 
We selected optimal cutoff values for the serum amylase and lipase values as predictors of 
post-ERCP pancreatitis based on their sensitivity and specificity and especially their positive 
predictive value (PPV) and negative predictive value (NPV), by using a prior probability 
value for post-ERCP pancreatitis of 4.2% (incidence rate among the cases in this study as a 
whole). 
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3. Results 
3.1 Incidence of post-ERCP pancreatitis 
Pancreatitis developed after 67 (4.2%) of the 1631 ERCP procedures. According to the JPN 
scores the pancreatitis was mild after 60 (3.7 %) of the procedures, moderate after 5 (0.3%), 
and severe after 4 (0.2%). There were no deaths in our series. Pancreatitis developed after 40 
(4.4%) of the 910 diagnostic ERCPs, and after 29 (4.0%) of the 721 therapeutic ERCPs. The 
difference between the incidence of post-ERCP pancreatitis after diagnostic ERCP and after 
therapeutic ERCP was not statistically significant.  
The incidence of post-ERCP pancreatitis after diagnostic ERCP in the Gabexate mesilate 
group, Nafamostat mesilate group, and Ulinastatin group was 4.7% (31/666), 3.8% (7/184), 
and 3.3% (2/66), respectively, and there were no statistically significant differences in the 
incidence of post-ERCP pancreatitis between the three groups. The incidence of post-ERCP 
pancreatitis after therapeutic ERCP in the Gabexate mesilate group, Nafamostat mesilate 
group, and Ulinastatin group was 4.4% (19/428), 3.4% (7/209), and 3.6% (3/84), 
respectively, and there were no statistically significant differences in the incidence of post-
ERCP pancreatitis between the three groups. 
3.2 Risk factors for post-ERCP pancreatitis 
3.2.1 Diagnostic ERCP 
3.2.1.1 Univariate analysis  
The univariate analysis revealed statistically significant associationss between an increased 
risk of post-ERCP pancreatitis and 4 of the13 patient-related factors and 4 of the 9 
procedure-related factors (Tables 1 and 2). The patient-related factors that significantly 
increased the risk of pancreatitis were: age 65 years or over, presence of hyperamylasemia 
and/or hyperlipasemia before ERCP, past or present pancreatitis and IPMN. The significant 
procedure-related risk factors according to the univariate analysis were: injection of contrast 
medium into the pancreatic duct score >= 3, brushing cytology in the pancreatic duct, IDUS, 
and endoscopic nasobiliary drainage (ENBD).  
3.2.1.2 Multivariate analysis 
Five risk factors were significant according to the multivariate analysis. Two were patient-
related factors, age (OR=1.043/1 yr increase in age) and presence of hyperamylasemia 
and/or hyperlipasemia before ERCP (OR=2.291), and the other three were procedure-
related factors, high contrast medium injection pressure into the pancreatic duct (OR=2.406/ 
1 point increase), brushing cytology in the pancreatic duct (OR=4.135), and IDUS 
(OR=4.373). The R-square value was 0.204. 
3.2.2 Therapeutic ERCP 
3.2.2.1 Univariate analysis  
The univariate analysis revealed a statistically significant association between an increased 
risk of post-ERCP pancreatitis and only one endoscopist-related factor: inexperienced 
endoscopist (Tables 3 and 4).  
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IPMN, intraductal papillary mucinous neoplasia 
ERCP: Patient-related Factors (ref 34)) 
Table 1. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Diagnostic 
 
ERCP: An Endocopist-related Factor and Procedure-related Factors (ref 34)) 
IDUS, intraductal ultrasonography; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary 
balloon dilation; ENBD, endoscopic nasobiliary drainage 
Table 2 Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Diagnostic 
Patient-related factors Pancreatitis Non-pancreatitis p value
(n=40) (n=870)
Significant
   Age (>=65years/<65years)    26/14     378/492 <0.001
   Hyperamylasemia and/or       
      hyperlipasemia (yes/no)    18/22    184/686 <0.001
   Past or present
      pancreatitis (yes/no) 9/31 76/773 0.004
  IPMN  12/28 131/739 0.011
Not significant
   Gender (male/female)     17/23    501/369 0.062
   Past-post ERCP
      pancreatitis(yes/no)     1/39       6/864 0.200
   Past or presenting
     cholangitis (yes/no)     1/39       79/791 0.151
   Periamupullary 
     diverticulum (yes/no)     3/37     66/804 0.984
   Chronic pancreatitis (yes/no)     5/35      97/773 0.791
   Pancreatic cancer (yes/no)      2/38      108/762 0.160
   Pancreas divisum (yes/no)      1/39       30/840 0.746
   Anomalous pancreatic-          
     biliary junction (yes/no)      2/38       25/845 0.438
   Bile duct stone (yes/no)      1/39      40/830 0.532
Endoscopist-related factor and Pancreatitis Non-pancreatitis p value
Procedure-related factors (n=40) (n=870)
Significant
   Injection pressure of contrast
     medium into the pancreatic
    duct (score 3,4/0-2)    29/11    348/522 <0.001
   Brushing cytology in the
     pancreatic duct (yes/no)   11/29     69/801 <0.001
   IDUS (yes/no)    8/32   55/815 <0.001
   ENBD (yes/no) 1/39 3/867 0.040
Not significant
   Endoscopist experience
  (<=200 ERCPs/>200 ERCPs) 9/31 125/745 0.156
   EST (yes/no)   0/40     1/869 0.830
   EPBD (yes/no)    0/40    0/870 N.E.
   Bile duct stone exploration
     (yes/no)   0/40     0/840 N.E.
   Brushing cytology in the         
     bile duct (yes/no)     1/39     44/826 0.466
   Biliary stenting (yes/no)     0/40     0/870 N.E.
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IPMN, intraductal papillary mucinous neoplasia 
Table 3. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Therapeutic 
ERCP: Patient-related Factors (ref34)) 
 
ERCP: An Endocopist-related Factor and Procedure-related Factors (ref34)) 
IDUS, intraductal ultrasonography; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary 
balloon dilation; ENBD, endoscopic nasobiliary drainage 
Table 4. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Therapeutic  
Patient-related factors Pancreatitis Non-pancreatitis p value
(n=29) (n=692)
Not Significant
   Age (>=65years/<65years)    19/10     391/301 0.337
  Gender (male/female)  21/8     435/257 0.300
   Hyperamylasemia and/or       
   hyperlipasemia (yes/no)    8/21     207/485 0.788
   Past or present
      pancreatitis(yes/no)     1/28    49/643 0.450
   Past-post ERCP
      pancreatitis(yes/no)     1/39        6/864 0.200
   Past or presenting
     cholangitis (yes/no)     13/16       313/379 0.966
   Periamupullary 
     diverticulum (yes/no)     8/21     115/577 0.123
   Chronic pancreatitis (yes/no)      1/28      18/674 0.780
   Pancreatic cancer (yes/no)     3/26      112/580 0.400
   Pancreas divisum (yes/no)      0/29       1/691 0.838
   IPMN(yes/no)    0/29     2/690 0.772
   Anomalous pancreatic-          
     biliary junction (yes/no)      1/28      6/686 0.165
   Bile duct stone (yes/no)      14/15      350/342 0.808
Endoscopist-related factor and Pancreatitis Non-pancreatitis p value
Procedure-related factors (n=29) (n=692)
Significant
   Endoscopist experience
     (<=200 ERCPs/>200 ERCPs)   8/21   62/630 <0.001
Not significant
   Injection pressure of contrast
     medium into the pancreatic
    duct (score 3,4/0-2)    5/24    59/633 0.106
   Brushing cytology in the
     pancreatic duct (yes/no)   0/29     10/682 0.514
   IDUS (yes/no)    0/29    6/686 615
   EST (yes/no)    5/24     98/594 0.642
   EPBD (yes/no)    8/21     114/578 0.118
   Bile duct stone exploration
     (yes/no)    7/22     156/536 0.841
   Brushing cytology in the         
     bile duct (yes/no)    1/28     20/672 0.861
   Biliary stenting (yes/no)     4/25     120/572 0.620
   ENBD (yes/no)     5/24    231/461 0.070
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3.2.2.2 Multivariate analysis 
Two risk factors were significant according to the multivariate analysis. One was an 
endoscopist-related factor, inexperienced endoscopist (OR=4.407), and the other was a 
procedure-related factor, high contrast medium injection pressure into the pancreatic duct 
(OR=1.693/ 1 point increase). The R-square value was 0.073. 
3.2.2.3 Multivariate analysis of the cases as a whole 
Six risk factors were significant according to the multivariate analysis for whole cases. Two 
were patient-related factors, age (OR=1.038/1 yr increase in age) and presence of 
hyperamylasemia and/or hyperlipasemia before ERCP (OR=1.807). One was an 
endoscopist-related factor, inexperienced endoscopist (OR=2.645), and the other three were 
procedure-related factors, high contrast medium injection into the pancreatic duct 
(OR=1.608/1 point increase), brushing cytology in the pancreatic duct (OR=2.605), and 
IDUS (OR=2.602). R-square value was 0.114. 
3.2.3 Prediction of pancreatitis following ERCP by the 4-h post-procedure serum 
amylase level and lipase level 
3.2.3.1 Diagnostic ERCP 
The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level 
after diagnostic ERCP showed good test performance, with an area under the curve of  
0.88 (95% CI: 0.85-0.91) and 0.94 (95% CI: 0.92-0.96), respectively (Figure 1). The 4-h  
  
The area under the curve of the amylase levels was 0.88 (95% CI: 0.85-0.91).  
The area under the curve of the lipase levels was 0.94 (95% CI: 0.92-0.96).  
Fig. 1. ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after 
diagnostic ERCP. 
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post-procedure serum lipase level was a more effective predictor of post–ERCP pancreatitis 
than the amylase level based on the areas under the ROC curves (p=0.025). 
3.2.3.2 Therapeutic ERCP 
The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level 
after therapeutic ERCP showed good test performance, with an area under the curve of 0.92 
(95% CI: 0.90-0.93) and 0.96 (95% CI: 0.94-0.97), respectively (Figure 2). The 4-h post-
procedure serum lipase level was a more effective predictor of post–ERCP pancreatitis than 
the amylase level, based on the area under the ROC curves (p=0.035). 
 
 
 
 
The area under the curve of the amylase levels was 0.92 (95% CI: 0.90-0.93).  
The area under the curve of the lipase levels was 0.96 (95% CI: 0.94-0.97).  
Fig. 2. ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after 
therapeutic ERCP. 
3.2.3.3 ERCP cases as a whole 
The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level 
after ERCP for the cases as a whole showed good test performance, with an area under the 
curve of 0.91 (95% CI: 0.89-0.92) and 0.96 (95% CI: 0.94-0.97), respectively (Figures 3).  
The 4-h post-procedure serum lipase level was a more effective predictor of  
post–ERCP pancreatitis than the amylase level based on the areas under the ROC curves 
(p=0.007). 
www.intechopen.com
 
Prediction of Post-ERCP Pancreatitis 
 
139 
 
The area under the curve of the amylase levels was 0.91 (95% CI: 0.89-0.92). 
The area under the curve of the lipase levels was 0.96 (95% CI: 0.94-0.97).  
Fig. 3. ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after 
ERCP in the cases as a whole. 
3.2.3.4 Optimal cutoff values for amylase and lipase 
The optimal cutoff values for amylase were five times (625 IU/l) the upper limit of the 
normal range in the diagnostic ERCP cases, therapeutic ERCP cases, and ERCP cases as a 
whole based on their sensitivity and specificity and especially on their PPV and NPV  
(Table 5). 
 
Post-ERCP pancreatitis (ref34)). PPV, positive predictive value; NPV, negative predictive value. 
Table 5. Diagnostic Accuracy of Various Amylase Cutoff Levels for Predicting  
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The optimal cutoff values for lipase were ten times (490 IU/l) the upper limit of the normal 
range in diagnostic ERCP cases, therapeutic ERCP cases, and ERCP cases as a whole based 
on their sensitivity and specificity and especially on their PPV and NPV (Table 6).  
 
Table 6. Diagnostic Accuracy of Various Lipase Cut-off Levels for Predicting Post-ERCP 
pancreatitis (ref34)). PPV, positive predictive value; NPV, negative predictive value.. 
4. Discussion 
Pancreatitis remains the most common complication of ERCP, occurring after 1% to 30% of 
procedures (4-15), and its reported incidence has varied with the thoroughness of follow-up, 
the definition used, factors related to patient susceptibility, case mix, types of maneuvers 
performed, and the endoscopist. Rates of pancreatitis of 2% to 9% have been typical in 
unselected large prospective series (6-14). The subjects of the present study were consecutive 
patients who underwent diagnostic or therapeutic ERCP, and the incidence rate of pancreatitis 
was 4.2% in the subjects as a whole, 4.4 % in the diagnostic ERCP group, 4.0 %. In therapeutic 
ERCP group. These figures are comparable to those reported in recent prospective studies in 
which the definition and study population were similar to those in our study. 
A number of specific risk factors, acting independently or in concert, have been proposed as 
predictors of post-ERCP pancreatitis (6-14). The present study assessed 23 risk factors that 
included patient-related, procedure-related, and endoscopist-related variables. The results 
of the multivariate analysis showed that older age, hyperamylasemia and/or 
hyperlipasemia before ERCP, endoscopist experience with fewer than 200 ERCPs, high 
contrast medium injection pressure into the pancreatic duct, brushing cytology in the 
pancreatic duct, and IDUS each increased risk independently. The results of this study also 
demonstrated that the risk of post-ERCP pancreatitis is as much related to patient 
characteristics as to endoscopic technique and/or maneuvers, as previously reported (6-
10,14). However, the limitation of the present study is that it was a retrospective study. In 
spite of the fact that data were obtained from consecutive ERCP cases, minimal bias must be 
taken into account. 
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Previous studies have suggested that early hyperamylasemia is useful as a predictor of post-
ERCP pancreatitis (18,19,32,33). Thomas et al. (19) found that a 4-h amylase level threefold 
higher than normal was a useful predictor of pancreatitis and had a sensitivity and specificity 
of 70% and 95.3%, respectively. Testoni et al. (18) reported that a serum amylase level fivefold 
higher than normal 4 h after the procedure is a reliable predictor of post-procedure 
pancreatitis, with a sensitivity of 68.4%. In the present study the ROC of both the 4-h amylase 
level and the 4-h lipase level after diagnostic ERCP showed good test performance, with an 
area under the curve of 0.88 and 0.94, respectively, and the ROC of both the 4-h amylase level 
and the 4-h lipase level after therapeutic ERCP also showed good test performance, with an 
area under the curve of 0.92 and 0.96, respectively. In addition, the ROC of both the 4-h 
amylase and the 4-h lipase level after ERCP in the cases as a whole showed good test 
performance, with an area under the curve of 0.91 and 0.96, respectively. The optimal cutoff 
values for the amylase level after diagnostic ERCP, therapeutic ERCP, and ERCP as a whole 
were 5 times (625 IU/l) the upper limit of the normal range, and the sensitivity and specificity 
of the cutoff value for the as a whole cases was 78.0% and 85.8%, respectively. The optimal 
cutoff values for the lipase level after diagnostic ERCP, therapeutic ERCP, and ERCP as a 
whole cases were 10 times (490 IU/l) the upper limit of the normal range, and their sensitivity 
and specificity in the cases as a whole were 94.9% and 86.4%. The results of this study 
confirmed that the 4-h post-procedure serum amylase and lipase level are good predictors of 
pancreatitis both after diagnostic ERCP and after therapeutic ERCP.  
Comparisons of measurements of various pancreatic enzymes as a means of detecting of acute 
pancreatitis other than post-ERCP pancreatitis have shown that the blood lipase level is almost 
as sensitive as the total blood amylase level and has better specificity (20). Other studies (21-23) 
have demonstrated that the blood lipase level is more sensitive than the blood amylase level, 
and still another study concluded that the blood lipase level is an important diagnostic 
indicator for acute pancreatitis and that measuring it should be given top priority (24). By 
contrast, few studies have compared measurements of various pancreatic enzymes as a means 
of diagnosing post-procedure pancreatitis (25-27). Panteghini et al. (25) found that the serum 
lipase level increased faster than the levels of the other enzymes measured and that the 
average peak in lipase level was the highest in post-procedure pancreatitis. Doppl et al. (26) 
concluded that serum lipase measurement is the most sensitive diagnostic test for post-ERCP 
pancreatitis. The results of the present large retrospective study demonstrated that serum 
lipase was a more effective marker than amylase for predicting post-ERCP pancreatitis both 
after diagnostic ERCP and after therapeutic ERCP, based on the area under the ROC curves. A 
further prospective study should be performed to confirm the superiority of serum lipase over 
amylase as a predictor of post-ERCP pancreatitis. 
In conclusion, the 4-h post-ERCP serum amylase level and the 4-h post-ERCP lipase level, in 
particular, were found to be a useful means of predicting pancreatitis both after diagnostic 
ERCP and after therapeutic ERCP in a large retrospective study in a single center. A 
prospective study should be undertaken to confirm the usefulness of the 4-h post-ERCP 
amylase and lipase levels as predictors of post-ERCP pancreatitis. 
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